Generic Name: obeticholic acid

Pronunciation: N/A

Abbreviation: OCA

Other Market Name: N/A

Drug Class: NAFLD/NASH Medications

Company: Intercept Pharmaceuticals

Approval Status: Experimental

Generic Version Available: No

Experimental Code: OCA

General Info

Ocaliva is a semi-synthetic bile acid analog that has been shown to help reduce markers of liver inflammation and fibrosis, as well as increase insulin sensitivity in liver disease patients. Ocaliva is in Phase 3 clinical trials as a possible treatment for NASH. Ocaliva is already FDA-approved for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. 


Dosing Info: N/A

Side Effects


Other Info

For information about Ocaliva’s use for PBC, visit

Last Reviewed: February 4, 2019